Serum amyloid P component does not circulate in complex with C4-binding protein, fibronectin or any other major protein ligand

Scandinavian Journal of Immunology

Volumn 56, Issue 1, 2002, Pages 85-93

  Sen, J W ^a   Heegaard, N H H ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4 BINDING PROTEIN; FIBRONECTIN; IMMOBILIZED ANTIBODY; PLASMA PROTEIN; SERUM AMYLOID P;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CROSSED IMMUNOELECTROPHORESIS; GEL PERMEATION CHROMATOGRAPHY; HUMAN; IMMUNITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRONECTINS; IMMUNOELECTROPHORESIS; INTEGRIN ALPHAXBETA2; LIGANDS; PRECIPITIN TESTS; SERUM AMYLOID P-COMPONENT;

EID: 0036427291     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2002.01109.x     Document Type: Article

References (57)

1. Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle I J, et al. Structure of pentameric human serum amyloid P component. Nature 1994;367:338-45.
2. Loveless RW, Floyd-O'Sullivan G, Raynes JG, Yuen C-T, Feizi T. Human serum amyloid P is a multispecific adhesive protein whose ligands include 6-phosphorylated mannose and the 3-sulphated saccharides galactose, N-acetylgalactosamine and glucuronic acid. EMBO J 1992;11:813-9.
3. Skinner M, Cohen AS. Amyloid P Component. Meth Enzymol 1988;163:523-36.
4. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in viva. J Clin Invest 1994;94:1390-6.
5. Tatsuta E, Sipe JD, Shirahama T, Skinner M, Cohen AS. Different regulatory mechanisms for serum amyloid A and serum amyloid P synthesis by cultured mouse hepatocytes. J Biol Chem 1983;258 (9):5414-8.
6. Pepys MB, Dash AC, Markham RE, Thomas HC, Williams BD, Petrie A. Comparative clinical study of protein SAP (amyloid P component) and C- reactive protein in serum. Clin Exp Immunol 1978;32 (1): 119-24.
7. Skinner M, Sipe JD, Yood RA, Shirahama T, Cohen AS. Characterization of P-component (AP) isolated from amyloidotic tissue: Half-life studies of human and murine AP. Ann N Y Acad Sci 1982;389:190-8.
8. Nelson SR, Tennent GA, Sethi D et al. Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta 1991;200 (2-3):191-9.
9. Robey FA, Liu T-Y. Limulin: A C-reactive protein from Limulus palyphemus. J Biol Chem 1981;56:969-75.
10. Scofield VL, Putambekar L, Schluter SF, Coombe DR. Serum amyloid P component (SAP) -like protein from Botryllid ascidians provides a clue to amyloid function. Dev Immunol 1992;3:67-84.
11. Cathcart ES, Comerford FR, Cohen AS. Immunologic studies on a protein extracted from human secondary amyloid. N Engl J Med 1965;273:143.
12. Cathcart ES, Shirahama T, Cohen AS. Isolation and identification of a plasma component of amyloid. Biochim Biophys Acta 1967; 147: 392-3.
13. Coria F, Castafio E, Prelli F et al. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 1988;58:454-7.
14. Hutchinson WL, Hohenester E, Pepys MB. Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Mol Med 2000;6 (6):482-93.
15. otto M, Hawkins PN, Bickerstaff MCM et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 1997;3:855-9.
16. Coker AR, Purvis A, Baker D, Pepys MB, Wood SP. Molecular chaperone properties of serum amyloid P component. FEBS Lett 2000;473 (2): 199-202.
17. ickerstaff MCM, Botto M, Hutchinson WL et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999;5:694-7.
18. Horvath A, Andersen I, Junker K et al. Serum amyloid P component inhibits influenza A virus infections: In vitro and in viva studies. Antivir Res 2001;52 (1):43-53.
19. Kimura T, Tani S, Matsumoto YY, Takeda T. Serum amyloid P component is the Shiga toxin 2-neutralizing factor in human blood. J Biol Chem 2001;276 (45):41576-9.
20. Noursadeghi M, Bickerstaff MC, Gallimore JR, Herbert J, Cohen J, Pepys MB. Role of serum amyloid P component in bacterial infection: Protection of the host or protection of the pathogen. Proc Natl Acad Sci USA 2000;97 (26): 14584-9.
21. Brown MR, Anderson BE. Receptor-ligand interactions between serum amyloid P component and model soluble immune complexes. J Immunol 1993;151:2087-95.
22. Schwalbe RA, Dahlbäck B, Nelsestuen GL. Heparin influence on the complex of serum amyloid P component and complement C4b-binding protein. J Biol Chem 1991;266:12896-901.
23. Garcia de Frutos P, Härdig Y, Dahlbäck B. Serum amyloid P component binding to C4b-binding protein. J Biol Chem 1995;270:26950-5.
24. de Frutos PG, Dahlbäck B. Interaction between serum amyloid P component and C4b-binding protein associated with inhibition of factor I-mediated C4b degradation. J Immunol 1994; 152:2430-6.
25. Bristow CL, Boackle RJ. Evidence for the binding of human serum amyloid P component to Clq and Fab gamma. Mol Immunol 1986;23 (10):1045-52.
26. Arbashov SF, Wang C, Nicholson-Weller A. Serum amyloid P component forms a stable complex with human C566. J Immunol 1997;158 (8):3830-5.
27. Schwalbe RA, Dahlbäck B, Nelsestuen GL. Independent association of serum amyloid P component, protein S, and complement C4b with complement C4b-binding protein and subsequent association of the complex with membranes. J Biol Chem 1990;265:21749-57.
28. Sorensen I J, Andersen O, Nielsen EH, Svehag S-E. Native human serum amyloid P component is a single pentamer. Scand J Immunol 1995;41:263-7.
29. Sorensen I J, Nielsen EH, Andersen O, Danielsen B, Svehag S-E. Binding of complement proteins Clq and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand J Immunol 1996;44 (4):401-7.
30. de Beer FC, Baltz ML, Holford S, Feinstein A, Pepys MB Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component. J Exp Med 1981; 154 (4): 1134-9.
31. Axelsen NH. Handbook of immunoprecipitation-in-gel techniques. Scand J Immunol 1983;17 (Suppl. 10).
32. Heukeshoven J, Dernick R. Neue ergebnisse zum mechanismus der silberfiirbung. In: Elecktrophorese Forum '86. BJ Radola, ed. München: Technische Universitäit München, 1986;22-7.
33. Heegaard NHH, Bjerrum OJ. Immunoblotting - general principles and procedures. In: Handbook of Immunoblotting of Proteins. OJ Bjerrum, NHH Heegaard, eds. Boca Raton, FL: CRC Press. 1988;1-25.
34. Mann M, Højrup P, Roepstorff P. Use of mass spectrometric molecular weight information to identify proteins in sequence databases. Biol Mass Spectrom 1993;22:338-45.
35. De Beer FC, Baltz ML, Holford S, Feinstein A, Pepys MB. Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component. J Exp Med 1981;154 (4): 1134-9.
36. Frutos P, Gd Hadie;rding Y, Dahlbäck B. Serum amyloid, p. component binding to C4b-binding protein. The J Biol Chem 1995;270 (45):26950-5.
37. Pepys MB, Dash AC, Munn EA et al. Isolation of amyloid P component (protein AP) from normal serum as a calciumdependent binding protein. Lancet 1977; 1:1029-31.
38. Van de Poel RH, Meijers JC, Bouma BN. Interaction between protein S and complement C4b-binding protein (C4 BP). Affinity studies using chimeras containing c4bp beta-chain short consensus repeats. J Biol Chem 1999;274 (21): 15144-50.
39. Dahlback B, Frohm B, Nelsestuen G. High affinity interaction between C4b-binding protein and vitamin K-dependent protein S in the presence of calcium. Suggestion of a third component in blood regulating the interaction. J Biol Chem 1990;265 (27): 16082-7.
40. Dahlback B, Hildebrand B. Degradation of human complement component C4b in the presence of the C4b-binding protein-protein S complex. Biochem J 1983;209 (3):857-63.
41. Nukatsuka M, Nagasawa S. Characterization of the interaction between human protein S and C4b-binding protein (C4bp). J Biochem (Tokyo) 1987;102 (3):599-605.
42. Schwalbe RA, Dahlbäck B, Nelsestuen GL. Independent association of Serum Amyloid P component, protein S, and Complement C4b with Complement C4b-binding protein and subsequent associatin of the complex with membranes. J Biol Chem 1990;265 (35):21749-57.
43. 1-glycoprotein. Hoppe Seyler's Z Physiol Chem 1972;353:1841-9.
44. Pepys MB, Rademacher TW, Amatayakul-Chantler Set al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 1994;91:5602-6.
45. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 1979;38:284-93.
46. Holm NE, Nybo M, Junker K, Toftedal HP, Rasmussen IM, Svehag SE. Localization of human serum amyloid P component and heparan sulfate proteoglycan in in vitro-formed Abeta fibrils. Scand J Immunol 2000;52 (2):110-2.
47. De Haas CJC. New insights into the role of serum amyloid P component, a novel lipopolysaccharide-binding protein. FEMS Immunol Med Microbiol 1999;26:197-202.
48. De Haas CJC, van der Tol ME, van Kessel KPM, Verhoef J, van Strijp JAG. A synthetic lipopolysaccharide-binding peptide based on amino acids 27-39 of serum amyloid P component inhibits lipopolysaccharide-induced responses in human blood. J Immunol 1998; 161:3607-15.
49. Ying S-C, Gewurz AT, Jiang H, Gewurz H. Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of Clq. J Immunol 1993;150:169-76.
50. Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Reports 1996;23:253-60.
51. Taylor PR, Carugati A, Fadok VA et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000;192 (3):359-66.
52. Botto M, Dell'Agnola C, Bygrave AE et al. Homozygous Clq deficiency causes glomerulonephritis associated with multiple apoptotic bodies [see comments]. Nat Genet 1998; 19 (1):56-9.
53. Hawkins PN, Myers M J, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: Biological targeting by circulating human serum amyloid P component. Lancet 1988; 1:1413-8.
54. Dhawan S, Fields RL, Robey FA. A novel peptide from amyloid P component supports cell attachment. Biochem Biophys Res Commun 1990;171:1284-90.
55. Pepys MB, Booth SE, Tennent GA, Butler PJG, Williams DG. Binding of pentraxins to different nuclear structures. C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol 1994;97:152-7.
56. Evans TC, Nelsestuen GL. Dissociation of serum amyloid P from C4b-binding protein and other sites by lactic acid: Potential role of lactic acid in the regulation of pentraxin function. Biochemistry 1995;34:10440-7.
57. Sorensen I J, Holm NE, Schroder L, Voss A, Horvath L, Svehag SE. Complexes of serum amyloid P component and DNA in serum from healthy individuals and systemic lupus erythematosus patients. J Clin Immunol 2000;20 (6):408-15.